In patients with acute coronary syndrome undergoing PCI and receiving clopidogrel, gender did not significantly impact 1-year MACE rates (22% in males vs 21.7% in females; P=1.00).
Cohort (n=288)
No
Does gender impact the incidence of major adverse cardiovascular events at 1 year in patients with acute coronary syndrome undergoing percutaneous coronary intervention and receiving clopidogrel therapy?
In patients with acute coronary syndrome undergoing PCI and receiving clopidogrel, gender does not significantly impact the incidence of major adverse cardiovascular events at 1 year when baseline presentations and treatments are comparable.
Absolute Event Rate: 22% vs 21.7%
p-value: p=1.00
There are high frequencies of worse clinical outcomes and major cardiovascular events (MACE) reported in women. We aimed to determine that comparable baseline presentation and contemporary percutaneous coronary intervention (PCI) techniques overcome the gender-based differences in MACE at 1 year follow-up study. This prospective cohort study enrolled 288 consecutive acute coronary syndrome patients (ACS) from September 2022 to March 2023 at Kuwait Teaching Hospital, Peshawar, Pakistan. All the enrolled patients were followed for 1 year and MACE were compared between males and females. Data was analyzed using SPSS version 26.0. There were no statistically significant differences observed between demographic factors including age, BMI, and waist (p value > 0.05). Similarly, no significant differences were observed between biochemical parameters in male and females (p value > 0.05). Men were more physically active (p value 0.001). Smoking and snuffing were significantly higher in male then in female (p values < 0.001) while female had higher rate of diabetes mellitus (DM) and hypertension (HTN) with p values < 0.001 and 0.03, respectively. Overall incidence of 1 year MACE was 22% in males while 21.7% in females (p value 1.00). The male gender had less cardiovascular events over time as compared to females. However, the differences were not statistically significant (p-value 0.96). When baseline presentations, PCI techniques, and post PCI medication are identical in patients with ACS, gender does not impact the MACE at 1 year post PCI.
Iqbal et al. (Fri,) conducted a cohort in Acute coronary syndrome (ACS) (n=288). Male gender vs. Female gender was evaluated on Major adverse cardiovascular events (MACE) at 1 year (p=1.00). In patients with acute coronary syndrome undergoing PCI and receiving clopidogrel, gender did not significantly impact 1-year MACE rates (22% in males vs 21.7% in females; P=1.00).